Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-08-13. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0001610717-26-000358
acquired disposedD
codeS
direct or indirectD
form4
is derivativefalse
issuer name10x Genomics, Inc.
labelOpen market sale
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0001610717-26-000358",
"acquired_disposed": "D",
"code": "S",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "10x Genomics, Inc.",
"label": "Open market sale",
"person_name": "STUELPNAGEL JOHN R",
"price": 58.725,
"role": "Director",
"security": "Class A Common Stock",
"shares": 3000,
"shares_owned_after": 348436,
"source_path": "edgar/data/1770787/0001610717-26-000358.txt",
"ticker": "TXG",
"transaction_date": "2026-08-11",
"value": 176175
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.